New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.
Haploidentical hematopoietic cell transplant (haplo-HCT) with post-transplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new-onset post-transplant diabetes mellitus (PTDM) following haplo-HCT are unknown. We examined PTDM incidence and outcomes after haplo-HCT with PTCY. Patients without diabetes receiving haplo-HCT (n=64) were analyzed for PTDM diagnosis (defined as blood glucose≥ 200 mg/dL). By day 100, 14 (22%) patients developed PTDM (median, 18 days). Hyperglycemia (blood glucose ≥ 200 mg/dL) preceded corticosteroids in 11 (79%) individuals. PTDM patients had increased death/relapse (p=0.029). PTDM occurs frequently, precedes corticosteroids, and leads to inferior outcomes following haplo-HCT. PTDM prophylaxis/treatment may improve HCT survival.
['Mangan|Brendan L|BL|', 'Patel|Dilan|D|', 'Chen|Heidi|H|', 'Gatwood|Katie S|KS|', 'Byrne|Michael T|MT|', 'Sengsayadeth|Salyka|S|', 'Goodman|Stacey|S|', 'Dholaria|Bhagirathbhai|B|', 'Kassim|Adetola A|AA|', 'Jagasia|Madan|M|', 'Chinratanalab|Wichai|W|', 'Culos|Kathryn A|KA|', 'Engelhardt|Brian G|BG|']
haploidentical hematopoietic cell transplant Post-transplantation Diabetes Mellitus Stem cell transplant